Meeting
2019 Genitourinary Cancers Symposium
Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic castration-resistant prostate cancer (mCRPC; CheckMate 650).
Authors
Padmanee Sharma
University of Texas MD Anderson Cancer Center, Houston, TX
Padmanee Sharma , Russell Kent Pachynski , Vivek Narayan , Aude Flechon , Gwenaelle Gravis , Matt D. Galsky , Hakim Mahammedi , Akash Patnaik , Sumit Kumar Subudhi , Marika Ciprotti , Tao Duan , Abdel Saci , Sarah Hu , G. Celine Han , Karim Fizazi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02985957
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 142)
DOI
10.1200/JCO.2019.37.7_suppl.142
Abstract #
142
Poster Bd #
A6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
First Author: Padmanee Sharma
Poster
2016 ASCO Annual Meeting
STARVE-PC: Biomarker-driven phase 2 study of ipilimumab plus nivolumab for AR-V7-expressing metastatic castration-resistant prostate cancer (mCRPC).
First Author: Karim Boudadi
Poster
2023 ASCO Genitourinary Cancers Symposium
Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001).
First Author: Shahneen Sandhu
First Author: Sylvie Lorenzen